Relugolix in Clinical Practice: The Best Route for All?

Lisa M. Cordes, Fatima Karzai, William D. Figg, Ravi A. Madan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and perhaps most importantly, pharmacologic characteristics must be considered.

Original languageEnglish
Pages (from-to)647-650
Number of pages4
JournalOncologist
Volume28
Issue number8
DOIs
StatePublished - Aug 2023
Externally publishedYes

Fingerprint

Dive into the research topics of 'Relugolix in Clinical Practice: The Best Route for All?'. Together they form a unique fingerprint.

Cite this